MAGEC2 and cancer: Since overexpression of cyclin E promotes cancer development, our work suggests that MAGE-C2 may play an oncogenic activity by decreasing cyclin E ubiquitylation and maintaining cyclin E at a level that favor cell cycle progression in cancer cells.